Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
06/11/2023 14:06
Nov 6 (Reuters) - Ayala Pharmaceuticals Inc ADXS.PK :
* AYALA PHARMACEUTICALS ANNOUNCES AL102 RECEIVES ORPHAN DRUG
DESIGNATION FOR DESMOID TUMORS
Source text for Eikon: ID:nGNXCNkPS
Further company coverage: ADXS.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ayala Pharmaceuticals
See all newsBrief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals
Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors